

David Regan of Sona Nanotech on bringing their rapid saliva Covid-19 test to the market

written by InvestorNews | March 8, 2022

In a recent InvestorIntel interview, Tracy Weslosky spoke with David Regan, CEO of [Sona Nanotech Inc.](#) (CSE: SONA | OTCQB: SNANF) about their rapid saliva COVID-19 test and about why Sona Nanotech is “the gold standard for nanotechnology”.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), David Regan said that Sona Nanotech has developed a unique biocompatible gold nanorod technology that has a wide variety of medical applications. Highlighting the absence of a rapid saliva covid-19 test in the market, David went on to provide an update on Sona Nanotech’s partnership with US FDA registered Arlington Scientific to bring Sona’s rapid saliva COVID-19 test to market. David also provided an update on the [appointment of two directors](#) to Sona Nanotech’s board with backgrounds with a NASDAQ-listed biotech company and Medtronic Canada.

To watch the full interview, [click here](#).

About Sona Nanotech Inc.

Sona Nanotech is a nanotechnology life sciences firm that has developed multiple proprietary methods for the manufacture of various types of gold nanoparticles. The principal business carried out and intended to be continued by Sona is the development and application of its proprietary technologies for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market. Sona Nanotech’s

gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona's gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards, including Health Canada and the FDA.

To learn more about Sona Nanotech Inc., [click here](#).

Disclaimer: *Sona Nanotech Inc. is an advertorial member of InvestorIntel Corp.*

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company" being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a

potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on [Sedar.com](https://www.sedar.com) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at info@investorintel.com.

David Regan on Sona Nanotech's rapid-result saliva based COVID-19 test

written by InvestorNews | March 8, 2022

In a recent InvestorIntel interview, Chris Thompson spoke with David Regan, CEO of [Sona Nanotech Inc.](https://www.sona-nanotech.com) (CSE: SONA | OTCQB: SNANF) about Sona's [partnership](#) with FDA registered Arlington Scientific to bring its rapid saliva-based COVID-19 test to market.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), David Regan said that Sona Nanotech is a nanotechnology life sciences company with a unique biocompatible gold nanorod platform technology that is free from any toxin. He went on to provide an update on Sona's rapid test development portfolio comprising of a saliva based COVID-19 test and a concussion

screening test, the types of which currently don't exist in the market. In the interview, David also provided an update on Sona's research around its gold nanorods for its use in targeted drug delivery and photothermal therapy.

To watch the full interview, [click here](#).

About Sona Nanotech Inc.

Sona Nanotech is a nanotechnology life sciences firm that has developed multiple proprietary methods for the manufacture of various types of gold nanoparticles. The principal business carried out and intended to be continued by Sona is the development and application of its proprietary technologies for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market. Sona Nanotech's gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona's gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards, including Health Canada and the FDA.

To learn more about Sona Nanotech Inc., [click here](#).

Disclaimer: Sona Nanotech Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company" being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on [Sedar.com](https://www.sedar.com) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at info@investorintel.com.

Sona Nanotech is seeking U.S.

FDA approval for its rapid COVID-19 saliva test

written by InvestorNews | March 8, 2022

Much to my chagrin, it appears this damn COVID virus is refusing to let us be. I guess one positive take-away is that we are learning about the Greek alphabet. I can't say I was familiar with omicron prior to last Thursday, but all of a sudden it's the most talked about Greek letter in the world. Along those lines it would appear we aren't going to shed this virus anytime soon (pun intended), so we are going to have to adapt to it so we can get back to as normal a lifestyle as possible. In my opinion, an easy to administer, reliable rapid test could go a long way towards returning us to our normal day-to-day activities while still giving confidence to all those around us that they are in a safe environment. Obviously, it would have to be more convenient than the one where it seems like they are trying to swab brain tissue behind your eyes, because I know I certainly won't be signing up to do that every day or two. But a simple saliva swab in the mouth, and 15 minutes later you've got the green light to do whatever, seems like a reasonable solution.

There are a lot of companies out there that are pursuing this holy grail of a reliable rapid test, but the one I want to talk about today is developing a saliva-based rapid screening test, for Coronavirus, derived from a bunch of other interesting applications for their technology. The company is [Sona Nanotech Inc.](#) (CSE: SONA | OTCQB: SNANF), and they have developed multiple proprietary methods for the manufacture of various types of gold nanoparticles and are experienced in the development of rapid, lateral flow assay, in-vitro, diagnostic tests. The Company is also involved in research and development

into other potential applications for its proprietary technologies.

What makes Sona (the Hindi word for gold) unique is that it has patented, **non-toxic**, metallic gold nanorods (GNRs) which are small particles whose surface plasmon resonance (SPR) frequencies can be altered by modifying their length and width, giving them properties useful in a host of applications, including diagnostics, optical biomedical imaging, and photothermal therapies, to name a few. I recognize that's a lot of science stuff but the key term in the last sentence to focus on is non-toxic. One of the major barriers in the application of GNR based materials is the presence of cetrimonium bromide (CTAB), a cytotoxin. After years of hard work, Sona was able to perfect the process and develop the ability to synthesize large volumes of high-quality gold nanorods free of CTAB. This opened the door to using GNRs as a drug delivery vehicle and for photothermal therapy.

If you check out the [Sona Nanotech](#) website there is some pretty fascinating stuff, even if I don't understand a bunch of it. However, we'll focus on the investment thesis for today. It should be somewhat obvious that a rapid COVID test is what is of greatest importance right now. On November 8th the Company announced a U.S. partnership and preliminary evaluation results for its [COVID-19 saliva test](#). Sona entered into a binding licensing agreement with U.S. FDA registered Arlington Scientific Inc. of Springville, Utah, to bring Sona's rapid saliva COVID-19 test to market. The market was pretty excited about this news as the stock popped 87% the day after the press release, and that was before anyone was aware of the COVID omicron variant. If an FDA Emergency Use Authorization is granted, Arlington will coordinate manufacturing and distribution of the test in the U.S. exclusively on a profit-

sharing basis. In other words, Arlington will make it and market it, meaning almost zero cost for Sona to move the product forward (Sona is on the hook for providing key biological materials for testing). This is a very important deal for a company that currently has no revenue and is pretty much focused on R&D.

There are plenty of other developments going on at Sona like a concussion test for mild traumatic brain injury that aims to detect a series of biomarkers enabling the screening for mild concussions, and a bovine tuberculosis test, which is being developed with a consortium of companies as part of a Canada/UK industrial research and development program. Both of which could be future sources of income for the Company but not likely on the scale of a rapid COVID test. Another interesting application of their technology is a possible advancement of radiation therapy in cancer cells by focusing on the treatment. Evidence suggests that GNRs could be more effective at killing tumors with less or no adverse reactions to healthy cells given that traditional methods of this type of treatment involve non-selective irradiation, damaging the normal tissue surrounding a tumor. Although maybe we'll save the discussion of these applications for another day.

For now, Sona could be in the right place at the right time. After some initial missteps, they have fine-tuned their rapid, saliva, COVID-19 test just in time for the next variant of concern to come along. With just over 65 million shares outstanding they have a market cap of roughly C\$28 million based on yesterday's close. A near-term catalyst could prove to be a better shot in the arm for Sona Nanotech than any vaccine.